GFAP RNA Oligonucleotide Modulation for Alexander Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no specific therapies for Alexander Disease (AxD), a rare and fatal leukodystrophy caused by GFAP mutations, leading to symptoms such as motor and cognitive delays, seizures, and intra-astrocytic inclusions, with current treatments limited to supportive care.
Innovation Solution
Development of compounds, particularly modified oligonucleotides, to reduce GFAP RNA activity and expression, thereby ameliorating symptoms of AxD, including motor delays, cognitive delays, seizures, and intra-astrocytic inclusions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive treatments are used for Alexander Disease, then symptoms can be managed, but no specific therapy addresses the underlying GFAP mutation
Solution Approach 1:
The patent extracts and targets the specific harmful element (mutant GFAP RNA) causing Alexander Disease using antisense oligonucleotides. The compounds are designed to specifically bind to and reduce the expression of mutant GFAP RNA transcripts, separating the treatment effect from general supportive care and directly addressing the genetic mutation.
Solution Approach 2:
The patent changes the molecular parameters of the treatment by using modified oligonucleotide structures (antisense compounds, siRNA, aptamers) that can specifically recognize and bind to GFAP RNA sequences. This molecular-level parameter change enables specific therapeutic action against the disease-causing RNA rather than symptomatic management.
2Reliability
If GFAP RNA expression is reduced using oligomeric compounds, then disease symptoms are ameliorated, but the complexity of compound design and delivery increases
Solution Approach 1:
The therapeutic approach is segmented into different types of oligomeric compounds (antisense oligonucleotides, siRNA, aptamers) that can be selected and optimized for specific targets within the GFAP RNA pathway. This segmentation allows for tailored treatment strategies targeting different aspects of GFAP RNA expression and function.
Solution Approach 2:
The patent uses oligomeric compounds as intermediary molecules that mediate between the therapeutic goal (reducing GFAP expression) and the biological target (GFAP RNA). These compounds serve as mediators that can be engineered with specific sequences and modifications to achieve precise control over GFAP RNA reduction while managing delivery challenges.
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of GFAP RNA in a cell or subject, and in certain instances reducing the amount of GFAP in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include motor delays, cognitive delays, paroxysmal deterioration, seizures, vomiting, swallowing difficulties, ataxic gait, palatal myoclonus, autonomic dysfunction, and presence of intra-astrocytic inclusions called Rosenthal fibers. Such leukodystrophies include Alexander Disease.